Sleeve lobectomy after neoadjuvant chemoimmunotherapy/chemotherapy for local advanced non-small cell lung cancer.
Sleeve lobectomy
neoadjuvant chemotherapy
neoadjuvant immunochemotherapy
non-small cell lung cancer (NSCLC)
Journal
Translational lung cancer research
ISSN: 2218-6751
Titre abrégé: Transl Lung Cancer Res
Pays: China
ID NLM: 101646875
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
entrez:
11
2
2021
pubmed:
12
2
2021
medline:
12
2
2021
Statut:
ppublish
Résumé
Sleeve lobectomy has been reported to be a safe procedure after neoadjuvant chemotherapy. We aim to evaluate the oncological and surgical outcomes of neoadjuvant chemoimmunotherapy (IO+C) for local advanced non-small cell lung cancer (NSCLC) patients who underwent sleeve lobectomy. NSCLC patients that underwent sleeve lobectomy between December 2016 and December 2019 were retrospectively included. Patients were divided into two groups: neoadjuvant IO+C and chemotherapy. Oncological, intraoperative and postoperative variables were compared. In total, 20 patients underwent sleeve lobectomy after neoadjuvant IO+C (n=10) or chemotherapy (n=10). In the neoadjuvant IO+C group, 8/10 (80%) patients achieved a partial response (PR), 1/10 (10%) patients had a complete pathological response (CPR), and 5/10 (50%) patients achieved a major pathological response (MPR). In the neoadjuvant chemotherapy group, only 3/10 (30%) patients had PR, and 3/10 (30%) patients achieved MPR. No complications were found in the neoadjuvant IO+C group, 1 chylothorax occurred in the neoadjuvant chemotherapy group. Other peri- and postoperative outcomes were similar: bleeding volume (365.00 Sleeve lobectomy for advanced NSCLC following IO+C is feasible, although the operations become more complex, neoadjuvant IO+C did not delay postoperative recovery.
Sections du résumé
BACKGROUND
BACKGROUND
Sleeve lobectomy has been reported to be a safe procedure after neoadjuvant chemotherapy. We aim to evaluate the oncological and surgical outcomes of neoadjuvant chemoimmunotherapy (IO+C) for local advanced non-small cell lung cancer (NSCLC) patients who underwent sleeve lobectomy.
METHODS
METHODS
NSCLC patients that underwent sleeve lobectomy between December 2016 and December 2019 were retrospectively included. Patients were divided into two groups: neoadjuvant IO+C and chemotherapy. Oncological, intraoperative and postoperative variables were compared.
RESULTS
RESULTS
In total, 20 patients underwent sleeve lobectomy after neoadjuvant IO+C (n=10) or chemotherapy (n=10). In the neoadjuvant IO+C group, 8/10 (80%) patients achieved a partial response (PR), 1/10 (10%) patients had a complete pathological response (CPR), and 5/10 (50%) patients achieved a major pathological response (MPR). In the neoadjuvant chemotherapy group, only 3/10 (30%) patients had PR, and 3/10 (30%) patients achieved MPR. No complications were found in the neoadjuvant IO+C group, 1 chylothorax occurred in the neoadjuvant chemotherapy group. Other peri- and postoperative outcomes were similar: bleeding volume (365.00
CONCLUSIONS
CONCLUSIONS
Sleeve lobectomy for advanced NSCLC following IO+C is feasible, although the operations become more complex, neoadjuvant IO+C did not delay postoperative recovery.
Identifiants
pubmed: 33569300
doi: 10.21037/tlcr-20-778
pii: tlcr-10-01-143
pmc: PMC7867787
doi:
Types de publication
Journal Article
Langues
eng
Pagination
143-155Informations de copyright
2021 Translational Lung Cancer Research. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tlcr-20-778). WL serves as an unpaid editorial board member of Translational Lung Cancer Research from Apr 2018 to Apr 2021. HL serves as a current section editor for this journal from Jan 2020 to Dec 2021. The other authors have no conflicts of interest to declare.
Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
N Engl J Med. 2018 May 24;378(21):1976-1986
pubmed: 29658848
J Thorac Dis. 2013 Aug;5 Suppl 3:S267-73
pubmed: 24040535
J Thorac Oncol. 2012 May;7(5):825-32
pubmed: 22481232
J Thorac Cardiovasc Surg. 1997 Nov;114(5):830-5; discussion 835-7
pubmed: 9375614
Ann Thorac Surg. 2018 Jul;106(1):178-183
pubmed: 29550207
J Thorac Cardiovasc Surg. 2019 Jul;158(1):269-276
pubmed: 30718052
Int J Cancer. 2019 Dec 1;145(11):3011-3021
pubmed: 31018251
J Clin Epidemiol. 2020 Jul;123:100-106
pubmed: 32259582
J Natl Compr Canc Netw. 2019 Dec;17(12):1464-1472
pubmed: 31805526
J Thorac Oncol. 2012 May;7(5):841-9
pubmed: 22722786
Ann Thorac Surg. 2014 Sep;98(3):975-83
pubmed: 25038013
J Thorac Oncol. 2016 Sep;11(9):1433-46
pubmed: 27448762
Lung Cancer. 2016 Jun;96:56-62
pubmed: 27133751
Lancet Oncol. 2014 Jan;15(1):e42-50
pubmed: 24384493
J R Coll Surg Edinb. 1956 Mar;1(3):169-86
pubmed: 13307666